FierceBiotech Radio on Valeant's fantasy football M&A, the gathering PCSK9 storm, and Novartis' alarming new campaign

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss Valeant Pharmaceuticals' latest reclamation projects, the bad-cholesterol horse race between Sanofi and Amgen, and Novartis' apparent horror-movie aspirations. Peace to Wes Craven.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to radio@fiercebiotech.com.

Read more on